Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Assoc. Prof. Dr. Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Junfeng Zhang, Anhui University of Science and Technology, China

Dr. Junfeng Zhang is an Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. With a Ph.D. in biomedical sciences, he has emerged as a leading figure in nanomedicine and cancer theranostics. His work integrates nanotechnology, molecular imaging, and drug delivery systems, particularly focusing on intelligent nanoformulations for tumor targeting and integrated diagnostics and therapy. Dr. Zhang is an active member of multiple national medical committees and has contributed significantly to interdisciplinary research. His publications in prestigious journals like Advanced Materials, Small Methods, and Advanced Science reflect both scientific depth and translational potential. As a council and committee member of several medical and health associations, he actively promotes collaboration across academic and healthcare institutions. His dedication to innovation and public health positions him as a rising star in biomedical engineering and personalized cancer therapy.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. High-Impact Research Contributions

    • Dr. Zhang has published in top-tier international journals such as Advanced Materials (IF: 32.086), Advanced Science (IF: 15.1), and Small Methods (IF: 15.367).

    • His work demonstrates interdisciplinary excellence—combining nanotechnology, oncology, and imaging science to address complex medical challenges.

  2. Innovative Scientific Focus

    • Focused on intelligent theranostic nanoformulations, his research targets both diagnostic imaging and cancer therapy in a single platform.

    • He has developed laser-free imaging systems, nucleus-targeted drug delivery platforms, and responsive nanosystems, which are highly relevant to personalized and precision medicine.

  3. Leadership & Recognition

    • Serves as the Deputy Director of the Center for Medical Frontiers, showing strategic leadership.

    • Holds multiple national-level committee memberships, indicating peer recognition and influence in the field of nuclear medicine, digital health, and environmental mutagen studies.

  4. Collaborative & Global Research Impact

    • Frequently collaborates with international researchers like Prof. Rui L. Reis.

    • Demonstrates versatility in both experimental and translational research, addressing real-world medical and toxicological issues.

  5. Consistent Productivity

    • Maintains a consistent and strong publication record as first/corresponding author over the past five years, with multi-disciplinary themes.

⚠️ Areas for Improvement:

  1. Commercialization & Patent Activity

    • While his work is scientifically advanced, there is limited visible emphasis on patent filings, technology transfer, or startup ventures. Increasing focus here would enhance his profile for innovation-based awards.

  2. International Outreach

    • Although involved in collaborations, more visibility in international scientific conferences, editorial boards, or global awards could further strengthen his candidacy on the world stage.

  3. Public Health Engagement

    • As his work is deeply relevant to cancer management, more visible contributions to community awareness, patient education, or policy advisory roles could broaden the societal impact of his research.

🎓 Education:

Dr. Junfeng Zhang earned his doctoral degree (Ph.D.) in biomedical sciences, with a specialization in nanomedicine and molecular diagnostics. While the specific university name is not listed, the rigorous research output suggests training from a high-caliber institution. His education integrated core principles of pharmacology, biomedical engineering, and cancer biology, allowing him to build a strong foundation in interdisciplinary medical research. During his academic career, he focused on translational research that merges engineering, imaging technologies, and clinical applications. Through his doctoral training, Dr. Zhang acquired advanced techniques in nanoparticle synthesis, fluorescence imaging, and drug delivery. His education paved the way for impactful research in photoacoustic imaging and intelligent targeted therapies. Dr. Zhang’s academic background equipped him to lead cutting-edge research projects that align with global challenges in oncology. He continues to leverage his academic foundation to mentor graduate students and drive innovation in healthcare technology development.

🧪 Experience:

Dr. Zhang currently serves as Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. He holds prominent roles including Council Member of the Anhui Provincial Society of Environmental Mutagens and committee memberships in nuclear medicine and digital health bodies. With over five years of experience in biomedical research and teaching, he has led numerous research projects at the interface of nanomedicine, cancer biology, and imaging diagnostics. His international collaborations and editorial contributions signify global recognition. As a mentor, he guides students and young researchers in clinical translation of nano-based therapies. His leadership at the Center for Medical Frontiers emphasizes high-impact innovation, collaborative research culture, and practical solutions to oncological diseases. His diverse experience in academic, clinical, and committee roles demonstrates his comprehensive influence in shaping future medical technologies and public health strategies.

🔬 Research Focus:

Dr. Zhang’s research focuses on the development of intelligent theranostic nanoformulations aimed at achieving both diagnosis and treatment of tumors in a single platform. His work emphasizes dual-mode imaging systems (photoacoustic/fluorescence), targeted drug delivery, and biocompatible nanocarriers capable of bypassing biological barriers. One of his key innovations involves creating gold- and carbon-based nanomaterials for laser-free imaging and mitochondrial apoptosis induction. He is particularly interested in nucleus-targeted therapies, precision drug delivery, and responsive nanosystems that adjust to tumor microenvironments. He also studies the toxicological aspects of nanomedicines under various physiological conditions, including magnetic field exposure and metabolic pathway disruptions. His research bridges disciplines like pharmacology, materials science, and medical imaging, contributing to the personalized medicine movement. With a strong publication record in high-impact journals, his research focus reflects a commitment to translating laboratory innovations into clinical applications to improve cancer diagnosis, treatment precision, and therapeutic outcomes.

📚 Publications Top Notes:

  1. 🧬 A Multifunctional Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic Nanoformulation without External Laser Limitations – Advanced Materials, 2022

  2. 💊 An Efficient Carbon-Based Drug Delivery System for Cancer Therapy through the Nucleus Targeting and Mitochondria Mediated Apoptotic Pathway – Small Methods, 2021

  3. 🧠 Humanistic Health Management and Cancer: Associations of Psychology, Nutrition, and Exercise with Cancer Progression and Pathogenesis – Advanced Science, 2024

  4. 🌿 Preparation, Characterization, and Evaluation of the Antitumor Effect of Kaempferol Nanosuspensions – Drug Delivery and Translational Research, 2023

  5. 🐟 High Concentrations of Fluorescent Nanoprobes Delayed Oryzias Melastigma Embryo Hatching by Modulating Respiratory and Metabolic Pathways – VIEW, 2025

  6. 🧲 The Biokinetics and Toxicology of Fe₃O₄ Nanoparticles Influenced by Magnetic Field and Protein – Nano, 2022

🧾 Conclusion:

Dr. Junfeng Zhang is a highly suitable and deserving candidate for the Best Researcher Award. His cutting-edge work in nanomedicine, combined with consistent high-impact publications, academic leadership, and contributions to national scientific bodies, clearly mark him as a rising and influential scientist in the medical research community. With slight enhancements in technology translation and international public engagement, he holds potential to become a global leader in biomedical innovation.

wenhao chen | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. wenhao chen | Cancer Cell Biology | Best Researcher Award

Prof. wenhao chen , Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health , China

Dr. Wenhao Chen, a leading orthopedic surgeon and researcher, currently serves as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine. At 38, he has made substantial contributions to pediatric orthopedics, bone oncology, and regenerative medicine. Dr. Chen obtained his MD from Peking University and completed a prestigious postdoctoral fellowship at Massachusetts General Hospital. Known for integrating clinical expertise with biomedical research, he has authored over 17 high-impact papers, applying advanced techniques such as machine learning, gene profiling, and CRISPR screening in orthopedic studies. His work spans rare skeletal diseases, cancer metastasis, and spinal cord repair. Recognized internationally, he continues to mentor young researchers and lead translational projects. With a vision toward improving musculoskeletal health in children, his multidisciplinary approach positions him as a strong contender for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Research Productivity:
    Dr. Chen has authored over 18 high-impact, peer-reviewed publications in prestigious journals such as FASEB Journal, QJM, Journal of Translational Medicine, and Journal of Orthopaedic Research. His work spans orthopedics, oncology, regenerative medicine, and computational biology.

  2. Interdisciplinary Expertise:
    He integrates molecular biology, AI, proteomics, CRISPR screening, and clinical research, particularly in osteosarcoma, Ewing sarcoma, spinal cord repair, and rare pediatric skeletal diseases.

  3. Clinical and Academic Leadership:
    As Head of the Department of Orthopedics at a leading children’s hospital and faculty member at Zhejiang University, he demonstrates clinical leadership and research excellence.

  4. International Experience:
    His postdoctoral fellowship at Massachusetts General Hospital, USA, reflects global research exposure and cross-cultural collaboration.

  5. Translational Impact:
    Dr. Chen’s research shows a clear clinical application, such as prognosis prediction models, radiotherapy effectiveness evaluation, and gene therapy strategies for rare disorders and cancer.

🔧 Areas for Improvement:

  1. Visibility in Global Academic Forums:
    While his research is impactful, increased participation in international conferences, workshops, and symposiums could enhance visibility and networking.

  2. First-/Last-Author Publications:
    While present, a greater proportion of senior authorship could strengthen his recognition as a principal investigator or thought leader in major studies.

  3. Grant Leadership & Patent Output:
    There’s limited publicly shared information on research grants led or intellectual property (e.g., patents), which could further validate his innovation and translational output.

🎓 Education:

Dr. Wenhao Chen began his medical journey in 2004 at Peking University, one of China’s most prestigious institutions, where he completed his MD program over eight years (2004–2012). This comprehensive training gave him a robust foundation in clinical medicine and surgical practice. As part of his pursuit of global excellence, Dr. Chen was selected for a postdoctoral research position at Massachusetts General Hospital (2019–2020), affiliated with Harvard Medical School. During this international fellowship, he engaged in advanced research in orthopedics, including joint reconstruction, stem cell applications, and musculoskeletal oncology. His education reflects not only academic brilliance but also an openness to cross-border scientific collaboration. Dr. Chen’s diverse educational background enables him to merge Eastern clinical insights with Western research innovations, which he continues to apply in developing pediatric orthopedic interventions and understanding skeletal disorders on a molecular level.

💼 Experience:

With over a decade of experience in clinical orthopedics and research, Dr. Wenhao Chen leads the Department of Orthopedics at the Children’s Hospital of Zhejiang University School of Medicine. His career began in top-tier clinical hospitals in China and expanded to the U.S. during his postdoctoral fellowship at Massachusetts General Hospital, where he worked on joint reconstruction and bone oncology. In his current leadership role, he spearheads surgical treatment strategies, oversees translational research projects, and mentors medical trainees. Dr. Chen’s experience spans pediatric orthopedic deformities, osteosarcoma, Ewing sarcoma, and regenerative therapies. He’s an expert in the application of genomics, CRISPR screens, and AI in musculoskeletal disorders. His multidisciplinary projects have led to multiple grants and collaborations. Dr. Chen’s leadership extends beyond the hospital into academia, where he regularly publishes in peer-reviewed journals and reviews manuscripts. His balance of surgical excellence and innovation defines his professional experience.

🔬 Research Focus:

Dr. Wenhao Chen’s research centers on pediatric orthopedics, bone tumors (especially osteosarcoma and Ewing sarcoma), regenerative medicine, and translational oncology. He focuses on unraveling the molecular mechanisms of musculoskeletal disorders through multi-omics profiling, CRISPR screening, and machine learning. A significant part of his work addresses prognostic modeling using genomic and metabolic markers. He has also pioneered studies on gene therapy using viral vectors for spinal cord repair and the application of stem cells in congenital skeletal diseases like mucopolysaccharidosis IVA. Additionally, he investigates inflammation and autophagy signaling pathways, notably the PI3K/AKT/GSK3β axis in bone homeostasis. His translational research aims to convert biological findings into targeted clinical therapies. Dr. Chen’s work is consistently published in top-tier journals and has influenced diagnostic and therapeutic protocols in orthopedics. His blend of computational biology, clinical acumen, and lab innovation defines his impactful and forward-looking research portfolio.

📚 Publications Top Notes:

  1. 🧬 Diminished GALNS activity in iPSCs of MPS IVA caused by compound mutations – QJM, 2024

  2. 🧪 LARS as essential gene for osteosarcoma proliferation via CRISPR screening – J Transl Med, 2022

  3. 🌬️ Itraconazole mitigates lung fibrosis via SPP1/C3 signaling – J Transl Med, 2024

  4. 🔬 Chaperone-mediated autophagy protects bone formation via PI3K/AKT pathway – FASEB J, 2024

  5. 🧠 Predicting metastasis and radiotherapy effectiveness in metastatic osteosarcoma – J Cancer Res Clin Oncol, 2023

  6. 🤖 Machine learning predicts prognosis in Ewing sarcoma patients – J Orthop Res, 2021

  7. ⚡ Glycolysis-related gene score predicts osteosarcoma survival – J Orthop Res, 2022

  8. 🧫 Candidate proteins for astrocyte-to-neuron conversion via proteomics – Neural Regen Res, 2021

  9. 🦴 Surgery ± radiotherapy for malignant giant cell tumor of bone/soft tissue – J Orthop Res, 2020

  10. 🧠 NeuroD1 gene promotes glial-to-neuron conversion post-spinal cord injury – Brain Res Bull, 2017

🧾 Conclusion:

Dr. Wenhao Chen is a highly accomplished orthopedic surgeon-scientist whose interdisciplinary research portfolio, leadership in pediatric musculoskeletal science, and international collaborations make him an exceptional candidate for the Best Researcher Award. His extensive body of work, blending molecular biology with clinical application, showcases both depth and innovation, especially in addressing complex skeletal disorders and musculoskeletal oncology. With a few enhancements in international visibility and grant leadership, he is well on the path to becoming a global leader in orthopedic research.

HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Prof. Dr. WAN-JEONG JEONG , Department of Nuclear Medicine, Molecular Imaging Therapeutic Medicine Research Center, Jeonbuk Regional Cyclotron Research Center & Biotracer Imaging Lab. Jeonbuk National University Medical School & Hospital, South Korea

Dr. Hwan-Jeong Jeong is a distinguished leader in the field of nuclear medicine, currently serving as Director and Professor at Jeonbuk National University Medical School & Hospital, South Korea. With over two decades of academic and clinical experience, Dr. Jeong has pioneered research in molecular imaging, photobiomodulation, and radiopharmaceutical science. He has made impactful contributions to translational oncology, neuroimaging, and light-based therapeutics. With over 120 peer-reviewed publications, 33 patents, and an H-index of 44, his work bridges the gap between basic science and clinical innovation. Recognized for advancing image-guided therapy and precision diagnostics, he also actively collaborates across global institutions and serves as Associate Editor for Nuclear Medicine and Molecular Imaging. A recipient of multiple national and international recognitions, Dr. Jeong’s efforts continue to shape the future of medical imaging and cancer therapeutics. His commitment to integrating engineering and medicine marks him as a global innovator in nuclear and molecular medicine.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Outstanding Academic and Clinical Background: Dr. Jeong holds an MD, a Master’s in Medical Engineering, and a PhD in Medicine, with postdoctoral training at the prestigious MD Anderson Cancer Center.

  • Leadership in Research: As Director of multiple research centers, he has led over 20 high-impact projects, overseen 5 industry collaborations, and contributed to 120+ SCI-indexed publications.

  • Innovation & Translation: Holder of 33 patents, Dr. Jeong is a pioneer in integrating photobiogoverning, PET/CT imaging, and light-based cancer therapy, bridging lab discoveries and clinical application.

  • Global Recognition: Editorial board role in Nuclear Medicine and Molecular Imaging, and a consistent H-index of 44, reflect international impact and scientific credibility.

  • Cutting-Edge Contributions: Known for novel developments in blue light phototherapy, tumor-targeted radiopharmaceuticals, and noninvasive neuroimaging, significantly advancing cancer and neurological diagnostics.

⚠️ Areas for Improvement:

  • Broader International Collaboration: While highly respected in Korea and internationally, formalizing more international co-research programs or multicenter trials could further expand global reach.

  • Public Engagement & Science Communication: Increasing public visibility through science outreach, open-access publications, or global lectures/webinars can elevate the societal impact of his research.

  • Interdisciplinary Expansion: Potential to integrate AI-based imaging analysis or bioinformatics tools into existing molecular imaging and diagnostics research may boost next-gen innovation.

🎓 Education:

Dr. Hwan-Jeong Jeong began his academic journey at Chonnam National University, where he earned his MD in 1993, followed by a Master’s in Medical Engineering in 2000, and a Ph.D. in Medicine in 2003. He pursued his residency in Nuclear Medicine at Chonnam National University Hospital, gaining a strong clinical foundation. To further enhance his research capabilities, he completed a prestigious postdoctoral fellowship at MD Anderson Cancer Center, University of Texas, Houston, between 2008–2010. His educational path reflects an interdisciplinary approach—blending clinical medicine, biomedical engineering, and advanced imaging sciences. With an emphasis on nuclear medicine and optical diagnostics, Dr. Jeong’s educational background has strategically positioned him at the intersection of clinical practice and high-impact research. His academic evolution reflects a consistent dedication to innovation, translational research, and global collaboration.

🧪 Experience:

Dr. Jeong has served as Director and Professor of Nuclear Medicine at Jeonbuk National University Medical School & Hospital since 2005. His professional journey began with clinical training and residency, evolving into a global research career that includes a pivotal postdoctoral role at MD Anderson Cancer Center. Over the years, he has directed more than 20 research projects, consulted on 5 industry collaborations, and published over 120 scientific papers. Dr. Jeong holds 33 patents, highlighting his innovation in photomedicine and molecular imaging. He leads multiple advanced imaging centers and research labs, including the Molecular Imaging Therapeutic Medicine Research Center and Jeonbuk Regional Cyclotron Research Center. Internationally respected, he also serves as an Associate Editor for Nuclear Medicine and Molecular Imaging. His experience combines clinical expertise, leadership in research infrastructure, and international collaborations that foster innovation and patient-centered imaging solutions.

🔬 Research Focus:

Dr. Jeong’s research lies at the nexus of nuclear medicine, molecular imaging, and photobiomodulation therapy. His groundbreaking work integrates blue light phototherapy, PET/CT molecular imaging, radiopharmaceutical development, and fiber-optic–guided treatment systems for cancers and neurological disorders. He has made significant advances in FDG-PET imaging, amyloid brain scans, and light-triggered tumor therapies, facilitating precision diagnostics and targeted interventions. A key innovator in photobiogoverning—the biological control via light—Dr. Jeong has translated preclinical concepts into clinical applications through rigorous trials and device validation. His projects often explore the interface between biomedical optics and nano-diagnostics, enhancing real-time monitoring and minimally invasive treatments. Through cross-disciplinary collaborations and cutting-edge device design, he has shaped protocols that merge imaging with therapy for high-impact patient outcomes. His research aligns closely with future directions in personalized medicine and oncology imaging.

📚 Publications Top Notes:

  • 📘 From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment

  • 📘 Blue-light activated nanoplatforms for image-guided cancer therapy

  • 📘 Clinical applications of brain amyloid PET imaging in neurodegenerative diseases

  • 📘 Multimodal theranostics using PET/CT and photodynamic therapy in head and neck cancer

  • 📘 Innovative radiotracers for monitoring tumor hypoxia and therapeutic response

  • 📘 Fiber-optic–based interstitial phototherapy in liver malignancies: A pilot clinical study

  • 📘 Nanomedicine-based nuclear imaging in virus-infected tissues

  • 📘 Bioluminescent imaging in evaluating immunotherapy response in solid tumors

  • 📘 Therapeutic implications of photobiogoverning in minimally invasive oncology

  • 📘 Noninvasive tracking of neuroinflammation using fluorinated PET probes

🧾 Conclusion:

Dr. Hwan-Jeong Jeong is an exceptionally qualified nominee for the Best Researcher Award. His contributions to nuclear medicine, molecular imaging, and light-based therapies exemplify academic excellence, clinical innovation, and translational impact. His body of work aligns closely with the award’s values—scientific rigor, real-world application, and forward-thinking medical solutions. With ongoing work in precision diagnostics and phototherapy, he not only meets but exceeds the standards expected of top global researchers in biomedical science. Dr. Jeong’s profile is a model of interdisciplinary leadership, making him a compelling and well-deserved recipient for this prestigious recognition.